Music, emotion, and the brain: Watanabe previews an article in this month's issue of *JNM* that for the first time uses PET to document specific brain receptor changes in response to frightening music . . . . ***Page 1497***

Physicians' view of oncologic PET: Karantanis and colleagues summarize the results of a survey of referring physicians' perspectives on PET/CT cancer imaging, including interactions with imaging specialists, confidence in appropriateness of indications, utility, and practical challenges . . . . . ***Page 1499***

PET/CT and outcome prognosis: Lim and colleagues investigate the value of staging ^{18}F-FDG PET/CT, beyond clinical risk factors, for predicting distant metastases and survival in patients after definitive chemoradiotherapy for oropharyngeal squamous cell carcinoma . . . . . ***Page 1506***

Early NSCLC treatment response: van Elmpt and colleagues describe the potential for early response assessment and prediction of overall survival based on ^{18}F-FDG uptake during radiotherapy in patients with non–small cell lung cancer. . . . ***Page 1514***



^{18}F-FLT PET and early response: Kishino and colleagues compare the utility of ^{18}F-FLT with that of ^{18}F-FDG for PET assessment of early locoregional clinical outcomes of chemoradiotherapy for head and neck squamous cell carcinomas . . . . ***Page 1521***

BSGC scintigraphy in DCIS detection: Spanu and colleagues evaluate the usefulness of breast-specific γ-camera scintigraphy in identification of ductal carcinoma in situ and correlate findings with screening mammography and histologic subtype . . . . . ***Page 1528***



New PET scanners for breast imaging: Iima and colleagues report on the diagnostic performance of 2 newly developed dedicated breast PET scanners (one O- and the other C-shaped) in patients with known or suspected breast cancer . . . . . ***Page 1534***

PET/CT in sarcoidosis: Sobic-Saranovic and colleagues assess the utility of ^{18}F-FDG PET/CT for detection of inflammation in granulomatous sites and management guidance in patients with chronic sarcoidosis . . . . . ***Page 1543***

Metaanalysis of PET and tinnitus: Song and colleagues review previous studies on PET evaluation of tinnitus using a coordinate-based technique to determine most commonly activated brain areas and to compare these results with those from other imaging modalities . . . . . ***Page 1550***



Clinical ^{18}F-desmethoxyfallypride PET: Amtage and colleagues define a clinical scan protocol with optimal quantification accuracy and timing for PET imaging with this promising tracer for longitudinal assessment of striatal dopamine in parkinsonism . . . ***Page 1558***

Dopamine release detection: Ceccarini and colleagues use simulation and human studies to determine the sensitivity and optimal timing of task administration for a single ^{18}F-fallypride PET protocol and provide a simplified model for detecting striatal and extrastriatal reward-induced dopamine release . . . . . ***Page 1565***



Scary music and monoamine receptors: Zhang and colleagues use ^{11}C-*N*-methylspiperone PET in healthy adults to investigate brain monoamine receptor changes induced by frightening music . . . . . ***Page 1573***

Fiber-based Cerenkov luminescence imaging: Liu and colleagues detail the development and testing of a prototype customized fiberscopic Cerenkov imaging system with potential for guiding minimally invasive surgery . . . . . ***Page 1579***

Islet cell apoptosis in diabetes: Watanabe and colleagues investigate the incidence of β-cell apoptosis in streptozotocin-treated mice and nonobese diabetic mice with ^{99m}Tc-annexin A5. . . . . ***Page 1585***

Immuno-PET for Met expression: Jagoda and colleagues describe initial studies with a radiolabeled experimental therapeutic mono-

clonal antibody with promise for PET assessment of hepatocyte growth factor receptor (Met) in cancers . . . . . *Page 1592*



PET and in vivo mGluR1 metrics: Yamasaki and colleagues use ^{18}F-FITM, a recently introduced PET ligand, to measure the affinity and density of metabotropic glutamate receptor subtype 1 in the brain of living rats . . *Page 1601*

^{18}F-FMISO data and Po_2: Bartlett and colleagues determine whether kinetic analysis of dynamic ^{18}F-fluoromisonidazole PET data provides better discrimination of tumor hypoxia than methods based on a simple tissue-to-plasma ratio . . . . . *Page 1608*

^{18}F-labeled glutamic acid and glutamine: Ploessl and colleagues report on preparation and comparative evaluation of ^{18}F-labeled glutamine and glutamic acid as tumor metabolic imaging agents . . . . . *Page 1616*



Anti-Trop-2 pretargeting epithelial cancers: Sharkey and colleagues prepare and evaluate a new anti-Trop-2× antihapten bispecific antibody with in vitro and in vivo studies to determine whether internalization properties would interfere with pretargeting in treatment of epithelial cancers . . . . . *Page 1625*

SNMMI guidelines in thyroid disease therapy: Silberstein and colleagues provide updated guidelines to assist practitioners in evaluating patients for ^{131}I therapy for benign or malignant diseases of the thyroid gland, performing safe and appropriate treatment, evaluating sequelae, and reporting results . . . . . *Page 1633*

ON THE COVER

PET images of a patient with hypopharyngeal cancer before radiation therapy, 3 wk after the initiation of radiation therapy, and 4 wk after the end of radiation therapy.

See page 1524.